Godavari Biorefineries has secured a United States patent for its invention titled “5-Hydroxy-1,4-Naphthalenedione for use in the treatment of cancer”, extending its intellectual property protection in life sciences.
The molecule represents a class of compounds that inhibit cancer and cancer stem cells, with potential applications across cancer types, including breast and prostate cancer.
The US patent expands Godavari Biorefineries’ international intellectual property footprint in life sciences and supports the company’s research into compounds with potential applications in cancer treatment.
“Our approach to innovation is guided by a larger purpose: advancing human health and wellbeing. The Sanskrit mantra ‘सर्वे सन्तु निरामयाः’, meaning ‘Health for All’, reflects this commitment. The grant of this US patent marks an important milestone in our life sciences research, strengthening our intellectual property and advancing our work on compounds with potential applications in cancer treatment. It reinforces our belief that scientific progress should strive to make better health and wellbeing accessible to all, contributing to a healthier future for everyone,” said Samir Somaiya, Chairman and Managing Director, Godavari Biorefineries Ltd.
Dr Sangeeta Srivastava, Executive Director, Godavari Biorefineries Ltd, said, “The development of novel molecules for potential applications in cancer treatment requires sustained scientific research and a deeper understanding of the mechanisms involved in cancer cell growth. This patent represents an important step in our research journey, particularly in exploring compounds that target cancer and cancer stem cells. Our focus remains on advancing scientific understanding and building on our research capabilities to explore potential approaches to complex human health challenges.”
Dr Srivastava is one of the four inventors of the patent, alongside Dr Sandip Gavade, Dr Prashant Kharkar and Dr Maithili Athavale.
The patent adds to Godavari Biorefineries Ltd’s intellectual property in life sciences and its research portfolio in cancer-related applications.